Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes - PubMed (original) (raw)
. 2016 Sep;17(5):e121-e129.
doi: 10.1016/j.cllc.2016.01.003. Epub 2016 Jan 21.
Maria L Santos-Zabala 2, Tunc Iyriboz 3, Kaitlin M Woo 4, Camelia S Sima 4, John J Fiore 5, Mark G Kris 5, Gregory J Riely 5, Piro Lito 5, Afsheen Iqbal 5, Stephen Veach 5, Stephanie Smith-Marrone 5, Inderpal S Sarkaria 6, Lee M Krug 7, Charles M Rudin 5, William D Travis 2, Natasha Rekhtman 2, Maria C Pietanza 5
Affiliations
- PMID: 26898325
- PMCID: PMC5474315
- DOI: 10.1016/j.cllc.2016.01.003
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
Jarushka Naidoo et al. Clin Lung Cancer. 2016 Sep.
Abstract
Background: Large cell neuroendocrine carcinoma (LCNEC) accounts for approximately 3% of lung cancers. Pathologic classification and optimal therapies are debated. We report the clinicopathologic features, treatment and survival of a series of patients with stage IV LCNEC.
Materials and methods: Cases of pathologically-confirmed stage IV LCNEC evaluated at Memorial Sloan Kettering Cancer Center from 2006 to 2013 were identified. We collected demographic, treatment, and survival data. Available radiology was evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria.
Results: Forty-nine patients with stage IV LCNEC were identified. The median age was 64 years, 63% of patients were male, and 88% were smokers. Twenty-three patients (n = 23/49; 47%) had brain metastases, 17 at diagnosis and 6 during the disease course. Seventeen LCNEC patients (35%) had molecular testing, of which 24% had KRAS mutations (n = 4/17). Treatment data for first-line metastatic disease was available on 37 patients: 70% (n = 26) received platinum/etoposide and 30% (n = 11) received other regimens. RECIST was completed on 23 patients with available imaging; objective response rate was 37% (95% confidence interval, 16%-62%) with platinum/etoposide, while those treated with other first-line regimens did not achieve a response. Median overall survival was 10.2 months (95% confidence interval, 8.6-16.4 months) for the entire cohort.
Conclusion: Patients with stage IV LCNEC have a high incidence of brain metastases. KRAS mutations are common. Patients with stage IV LCNEC do not respond as well to platinum/etoposide compared with historic data for extensive stage small-cell lung cancer; however, the prognosis is similar. Prospective studies are needed to define optimum therapy for stage IV LCNEC.
Keywords: Brain metastases; KRAS mutation; Platinum-etoposide chemotherapy; Small cell lung carcinoma; Stage IV.
Copyright © 2016 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure
The authors have stated that they have no conflicts of interest.
Figures
Figure 1. Microscopic Images of a Representative Case of LCNEC. (A) Low-Power and (B) High-Power Images of H&E-Stained Sections Demonstrating Classic LCNEC Morphology, Including Neuroendocrine Architecture (Nesting With Peripheral Palisading and Rosettes), High Mitotic Rate and Necrosis, and Non—Small-Cell Cytologic Features (Abundant Cytoplasm, Prominent Nucleoli). Immunohistochemistry for Synaptophysin (C) and CD56 (D) Shows Diffuse Labeling, Supporting Neuroendocrine Differentiation
Abbreviations: H&E = hematoxylin and eosin; LCNEC = large cell neuroendocrine carcinoma.
Figure 2. (A) Time to Progression for Patients With De Novo Stage LCNECs at Diagnosis (n = 21) Compared With Those With Recurrent, Metastatic Disease After Having Initially Presented With Stage I/II/III Disease (n = 9). (B) Time to Progression for Patients Who Received First-Line Chemotherapy Platinum/Etoposide (n = 20), Versus Those Who Received an Alternative Regimen (n = 10). (C) Overall Survival for Patients With De Novo Stage IV LCNECs at Diagnosis (n = 32) Compared With Those With Recurrent, Metastatic Disease After Having Initially Presented With Stage I/II/III Disease (n = 13). (D) Overall Survival for Patients Who Received First-Line Chemotherapy With Platinum/Etoposide (n = 26), Versus Those Who Received an Alternative Regimen (n = 11)
Abbreviations: E = etoposide; LCNEC = large cell neuroendocrine carcinoma; OS = overall survival; Plt/E = platinum/etoposide; TTP = time to progression.
Similar articles
- The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. Zhuo M, et al. Clin Cancer Res. 2020 Feb 15;26(4):892-901. doi: 10.1158/1078-0432.CCR-19-0556. Epub 2019 Nov 6. Clin Cancer Res. 2020. PMID: 31694833 Free PMC article. - Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT, Li Y, Yan LX, Zhu ZF, Dong XR, Chu Q, Wu L, Zhang HM, Xu CW, Lin G, Yu ZY, Hu J, Zhu B, Wang HJ, Yang F, Song ZB, Han ZB, Li MX, Lin J, Wu YL, Wang JL, Zhong WZ. Zhang JT, et al. Lung Cancer. 2020 Jan;139:118-123. doi: 10.1016/j.lungcan.2019.11.004. Epub 2019 Nov 11. Lung Cancer. 2020. PMID: 31775086 - Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E. Rossi G, et al. J Clin Oncol. 2005 Dec 1;23(34):8774-85. doi: 10.1200/JCO.2005.02.8233. J Clin Oncol. 2005. PMID: 16314638 - Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y, Chen Y, Yang Z, Qian F, Hu M, Lu J, Zhang Y, Zhang W, Wang K, Han B. Wang Y, et al. Ann Surg Oncol. 2022 Sep;29(9):5666-5678. doi: 10.1245/s10434-022-11610-4. Epub 2022 May 11. Ann Surg Oncol. 2022. PMID: 35543906 Review. - Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.
Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Iyoda A, et al. Ann Thorac Surg. 2007 Aug;84(2):702-7. doi: 10.1016/j.athoracsur.2007.03.093. Ann Thorac Surg. 2007. PMID: 17643676 Review.
Cited by
- Application of the 5th WHO Guidelines for the Diagnosis of Lung Carcinoma in Small Lung Biopsies in a Tertiary Care Center: Is Insecurity of Pathologists for the Accurate Diagnosis Justified?
Beckert M, Meyer C, Papadopoulos T, Levidou G. Beckert M, et al. Diagnostics (Basel). 2024 Sep 21;14(18):2090. doi: 10.3390/diagnostics14182090. Diagnostics (Basel). 2024. PMID: 39335769 Free PMC article. - An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.
Stefàno E, De Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M, Fanizzi FP. Stefàno E, et al. Int J Mol Sci. 2024 Aug 6;25(16):8568. doi: 10.3390/ijms25168568. Int J Mol Sci. 2024. PMID: 39201255 Free PMC article. Review. - CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma.
Kim B, Zhang S, Huang Y, Ko KP, Jung YS, Jang J, Zou G, Zhang J, Jun S, Kim KB, Park KS, Park JI. Kim B, et al. Cell Rep. 2024 Jun 25;43(6):114286. doi: 10.1016/j.celrep.2024.114286. Epub 2024 May 25. Cell Rep. 2024. PMID: 38796854 Free PMC article. - Prognostic factors and predictive models for patients with lung large cell neuroendocrine carcinoma: Based on SEER database.
Li W, Huang Q, He X, He Q, Lai Q, Yuan Q, Deng Z. Li W, et al. Clin Respir J. 2024 Apr;18(4):e13752. doi: 10.1111/crj.13752. Clin Respir J. 2024. PMID: 38606731 Free PMC article. - Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y, Wakuda K, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Ko R, Ono A, Naito T, Murakami H, Sugino T, Gon Y, Takahashi T. Iida Y, et al. Sci Rep. 2024 Apr 1;14(1):7641. doi: 10.1038/s41598-024-58327-w. Sci Rep. 2024. PMID: 38561461 Free PMC article.
References
- Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53. - PubMed
- Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134:1628–38. - PubMed
- Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44. - PubMed
- Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 2004.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous